2007
DOI: 10.2165/00003495-200767160-00004
|View full text |Cite
|
Sign up to set email alerts
|

Estrogen Receptor Modulators and Down Regulators

Abstract: Endocrine treatments have been used in breast cancer since 1896, when Beatson reported on the results of oophorectomy for advanced breast cancer. In the second half of the last century, different endocrine-based compounds were developed and, in this review, the role of the selective estrogen receptor modulators (SERMs) and selective estrogen receptor down regulators (SERDs) in the postmenopausal setting are discussed. Tamoxifen is the most investigated and most widely used representative of these agents, and h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
19
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 45 publications
(19 citation statements)
references
References 115 publications
0
19
0
Order By: Relevance
“…In spite of these beneficial effects, estradiol stimulation also influences the pathological processes of hormone-dependent cancers of breast, endometrial, prostrate, ovary and many other type of malignant tumors [5,6]. The important finding of the hormone responsiveness of ER+ve breast cancers, triggered the development of molecules which can compete with estradiol at its receptor and counterbalance its proliferative action [7]. The discovery of non-steroidal antiestrogen, tamoxifen as the therapy of choice for patients with ER+ve breast cancer [8] revolutionized the approach to regulate the endocrine system by disrupting the signalling cascade.…”
Section: Introductionmentioning
confidence: 99%
“…In spite of these beneficial effects, estradiol stimulation also influences the pathological processes of hormone-dependent cancers of breast, endometrial, prostrate, ovary and many other type of malignant tumors [5,6]. The important finding of the hormone responsiveness of ER+ve breast cancers, triggered the development of molecules which can compete with estradiol at its receptor and counterbalance its proliferative action [7]. The discovery of non-steroidal antiestrogen, tamoxifen as the therapy of choice for patients with ER+ve breast cancer [8] revolutionized the approach to regulate the endocrine system by disrupting the signalling cascade.…”
Section: Introductionmentioning
confidence: 99%
“…Although the inhibitory activity of the R7-conjugated peptide 5 against ER−coactivator interactions was slightly decreased compared with that of the R7-unconjugated peptide 2 (IC 50 : 13 nM), 5 still exhibited potent activity. The dominant conformations of the peptides were analyzed based on H-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-NH 2 PERM-1-R7 (4) H-Lys-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-(Gly) 3 -(Arg) 7 -NH 2 PERM-3-R7 (5) H-Arg-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Npg-Leu-Gln-(Gly) 3 -(Arg) 7 -NH 2 SRC-1-R7 (6) H-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-(Gly) 3 -(Arg) 7 -NH 2 YR7 (7) H-Tyr-(Arg) 7 Information about the synthesis and purification of the peptides and the protocols of the in vitro assays. This material is available free of charge via the Internet at http://pubs.acs.org.…”
Section: ■ Conclusionmentioning
confidence: 99%
“…Since estrogens are well known to play crucial roles in breast cancer development, much effort has been devoted to block estrogen formation [2]. The most widely used therapy for antagonizing estrogen receptor (ER) function is the antiestrogen tamoxifen (TAM), which binds to the ER and blocks downstream signaling [3]. However, current breast cancer therapies with TAM achieve meaningful clinical results in only 40% of patients because drug resistance usually develops within couple of years of treatment.…”
Section: Introductionmentioning
confidence: 99%